For over half a decade, the healthcare industry has poured more than $2.5 billion into value-based care (VBC) initiatives specifically designed to transform the landscape of kidney disease management. The intent was clear: move away from the traditional, fragmented fee-for-service model and toward a proactive, outcomes-based framework that emphasizes chronic disease management and improved dialysis delivery.
Yet, despite this massive influx of capital and a proliferation of innovative care models, the most critical metric for hospital operators and taxpayers remains stubbornly stagnant: hospital spending. As new data emerges, the healthcare sector is being forced to confront an uncomfortable truth—the problem may not be the amount of capital deployed, but rather the strategic target of the intervention.
The Chronology of a Misaligned Strategy
The evolution of kidney care in the United States has been marked by a series of well-intentioned policy shifts, yet each has struggled to address the underlying economic drivers of inpatient kidney care.
- 2019-2021: The rise of VBC kidney care models begins, with private equity and venture capital flooding the space. The focus is primarily on managing Stage 3 and 4 Chronic Kidney Disease (CKD) through outpatient clinics and optimizing dialysis transitions.
- February 2026: The Centers for Medicare & Medicaid Services (CMS) releases the second annual evaluation of the Kidney Care Choices (KCC) model. The report highlights successes in clinical quality, home dialysis adoption, and transplant rates, but reveals a $305 million increase in net Medicare expenditures.
- January 2026: CMS shifts the goalposts by mandating participation in the Transforming Episode Accountability Model (TEAM) for 741 hospitals, signaling a move toward episode-based financial accountability for cardiac procedures.
The central issue in this chronology is a timing mismatch. Current VBC models are designed to manage long-term chronic progression, but they consistently miss the "point of impact"—the specific hospitalization event that triggers acute kidney injury (AKI) and sets the patient on a downward trajectory of multi-year inpatient costs.
Supporting Data: Why KCC Fell Short
The Lewin Group’s analysis of the KCC model provides a masterclass in the limitations of current strategies. While the model succeeded in achieving clinical milestones, it failed to curb the most expensive component of care: the hospital admission.
The data suggests that the "cascade of events"—where a single acute stressor leads to systemic decline—is occurring far earlier than these models are designed to monitor. When a patient with underlying, potentially undiagnosed CKD enters the hospital for a separate issue, their renal reserve is often already depleted.
According to the data, 30 to 40 percent of cardiac surgery patients are already carrying CKD into the operating room. When these patients undergo surgery, the physiological stress—fluctuations in blood pressure, inflammatory responses, and blood flow alterations—acts as an accelerant. If the kidneys are already struggling, this acute stressor leads to AKI, which then necessitates prolonged ICU stays, potential readmissions, and an increased likelihood of long-term dialysis dependence.
The KCC model targeted the management of the chronic condition but failed to account for the acute stressors that occur within the hospital walls, where the bulk of the financial liability is actually generated.
The Acute Event: The "Point of No Return"
To understand why current models are failing to reduce spending, one must look at where hospital economics are truly determined. In clinical terms, "renal reserve" is the kidney’s ability to compensate for stress. A healthy patient can handle the physiological trauma of a cardiac procedure. A patient with unrecognized or early-stage CKD cannot.
When an acute event occurs in the OR or the ICU, the patient’s kidney function is pushed past its threshold. This is the moment where the trajectory of the patient’s health—and the hospital’s financial outcome—is locked in.
Because chronic care models are largely outpatient-focused, they are effectively "blind" to this critical window. By the time a patient is discharged from the hospital after an AKI event, the damage is often permanent. The subsequent costs—rehabilitation, skilled nursing facility (SNF) placement, and recurrent readmissions—are effectively "baked in" to the patient’s future.
The industry has been trying to stop the fire by pruning the branches of the tree, while the fire is actually burning at the roots: the acute surgical and intensive care environment.
The New Financial Reality: The TEAM Model
The landscape is undergoing a tectonic shift. For the past decade, hospital economics viewed AKI as an incidental complication of surgery—a unfortunate but manageable byproduct. However, with the implementation of the TEAM model, that perspective is now a financial liability.
By mandating participation for nearly 750 hospitals, CMS is effectively forcing institutions to own the outcome of the entire cardiac surgery episode. Under the TEAM model:
- Financial Accountability: Every negative consequence of an AKI—extended ICU days, SNF costs, and readmissions—now hits the hospital’s margins directly.
- Performance-Based Payments: Quality performance metrics can now adjust payments by up to ±20 percent.
- No Opt-Out: With no ability to avoid the program, hospitals are now directly incentivized to protect kidney function during the surgical episode.
This is a massive pivot. For the first time, the economic incentive to prevent AKI is aligned with the clinical imperative to protect renal function. Hospitals can no longer view kidney failure as an inevitable complication; they must view it as an avoidable cost driver that, if left unchecked, will jeopardize their financial viability under the new CMS mandate.
Official Responses and Strategic Implications
The implications for health systems are profound. Innovators and hospital leaders who recognize this shift will likely be the ones to thrive in the new, high-stakes environment.
The current consensus among health policy analysts is that the "innovation problem" in kidney care is a misnomer. We have the technology to monitor and protect renal function; we have the surgical protocols to manage blood pressure and inflammatory response. What we lack is the organizational bridge between the "chronic care" mindset and the "acute intervention" reality.
"The lesson from the KCC evaluation is that kidney care doesn’t have an innovation problem," says John Erbey, CEO and Founder of Roivios. "The real issue is one of timing. During a high-risk clinical event, when kidney function is vulnerable but still recoverable, this is where a targeted intervention can produce enormous downstream economic benefits."
Erbey’s focus on the "Renal Assist Device" (RAD) highlights a growing trend: technology designed specifically for the acute environment, aimed at sustaining kidney function during periods of maximum stress. This represents the next frontier of kidney care—moving from managing patients in the clinic to supporting them in the OR.
Conclusion: The Unrealized Opportunity
The $2.5 billion investment into kidney-focused VBC was not a waste, but it was an education. It taught the healthcare industry that while chronic disease management is essential, it is insufficient to address the acute hospital costs that drive Medicare spending.
The future of kidney care lies in the intersection of high-risk surgery and proactive, acute-phase renal support. As hospitals face the rigid financial accountability of the TEAM model, the incentive to change the standard of care has never been higher.
For health systems, the path forward is clear: integrate kidney protection into the surgical and intensive care workflow. Those who treat the kidney as a high-priority asset during the most vulnerable moments of a patient’s hospital stay will find that they have unlocked the single largest, most overlooked opportunity in modern healthcare. The solution has been hiding in plain sight—not in the clinic, but in the operating room.
John Erbey is the CEO and Founder of Roivios. With over 25 years of leadership in the medical sector and a Ph.D. from the University of Pittsburgh, he is a leading voice in the shift toward transformative kidney health management.
